Search

A 77-year-old man experienced diffuse alveolar haemorrhage (DAH) after receiving the varicella-zoster-virus vaccine. The man had a medical history of AL amyloidosis, IgG multiple myeloma, and asthma. He presented to the emergency department with symptoms of shortness of breath, haemoptysis, and fever. He was admitted to the ICU and treated with steroids and antibacterials. Despite improvement, he continued to experience shortness of breath and haemoptysis. Bronchoscopy confirmed a diagnosis of DAH caused by the vaccine. The man was discharged home on steroids after his condition improved. [Extracted from the article]

In a retrospective cohort study, three patients were described who developed aseptic meningitis, optic neuritis, or Guillain-Barre syndrome after receiving the tozinameran vaccine, Varicella zoster virus vaccine, or influenza virus vaccine. The patients received these vaccines for immunization and subsequently experienced these adverse reactions. The study did not provide specific details about the patients' ages, sexes, dosages, durations of treatments, or outcomes. [Extracted from the article]

A 52-year-old man experienced a cutaneous hypersensitivity reaction while being treated with dulaglutide for type 2 diabetes. The reaction occurred after the dose of dulaglutide was increased, resulting in a pruritic, erythematous, maculopapular rash on the abdomen at the injection site. The rash resolved after several days and the man's dulaglutide treatment was discontinued. [Extracted from the article]

A 16-year-old girl experienced a lack of efficacy after receiving the varicella-zoster-virus vaccine against the herpes zoster virus. Despite being fully vaccinated against the varicella zoster virus at the ages of 1 and 6, she presented with a skin rash that was diagnosed as chickenpox through a positive polymerase chain reaction (PCR) test. The girl was treated with valaciclovir for 7 days, and her symptoms completely disappeared after the treatment. [Extracted from the article]

A multicenter retrospective observational cohort study of 117 patients with refractory ulcerative colitis found that some patients developed various toxicities while being treated with ustekinumab or tofacitinib. Four patients receiving ustekinumab developed Clostridioides difficile infection, herpes simplex virus infection, symptomatic varicella zoster reactivation, and colorectal cancer. Three patients receiving tofacitinib developed respiratory tract infections, colorectal cancer, and central retinal vein occlusion. One patient who developed central retinal vein occlusion discontinued treatment with tofacitinib. The study does not provide information on the duration of treatments or outcomes. [Extracted from the article]

A retrospective case series involving 16 patients at the MS Research Center of Sina and Qaem hospital found that three patients developed chickenpox and headache while being treated with natalizumab for multiple sclerosis. The first patient, a 27-year-old woman, developed self-limited chickenpox and discontinued natalizumab due to a high JC virus index. The second patient, a 16-year-old man, also developed mild chickenpox but continued natalizumab and received a varicella-zoster virus vaccine. The third patient, a 43-year-old man, experienced mild headache and continued natalizumab, eventually receiving the varicella-zoster virus vaccine. [Extracted from the article]

A 23-year-old man developed a varicella zoster virus (VZV) infection while undergoing immunosuppressant therapy with mycophenolate-mofetil, prednisolone, and tacrolimus. He presented with a high-grade fever, chills, and a generalized rash. The man had a history of end-stage renal disease and had undergone a renal transplant. He was treated with aciclovir and his symptoms improved. The VZV infection was believed to be related to the immunosuppressant medications he was taking. [Extracted from the article]

A 31-year-old woman experienced vaccine failure while receiving treatment with tozinameran for COVID-19. She reported a tingling sensation and itching in her right axilla on Day 0, and on Day 6, her son tested positive for COVID-19 while she remained asymptomatic. Despite receiving three doses of the tozinameran vaccine, the woman tested positive for SARS-CoV-2, indicating vaccine failure. After a medical interview, she was diagnosed with herpes zoster and treated accordingly. Her symptoms resolved after 14 days of treatment. [Extracted from the article]

This article from Reactions Weekly describes two cases of disseminated varicella zoster infection in patients undergoing treatment for lupus nephritis. The first case involves a 46-year-old woman who developed the infection while receiving prednisolone, tacrolimus, and mycophenolate-mofetil. Despite treatment with aciclovir and glucocorticoids, she experienced liver dysfunction and disseminated intravascular coagulation, ultimately leading to her death. The second case involves a 26-year-old man who developed the infection while receiving prednisolone and mycophenolate-mofetil. Despite treatment with aciclovir, plasma exchange, and haemodiafiltration, he developed septic shock and died. These cases highlight the lack of efficacy of the treatments used for disseminated varicella zoster infection in these patients. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 57-year-old woman developed CNS varicella zoster vasculitis and acute retinal necrosis during treatment with natalizumab monthly for multiple sclerosis. She presented to the hospital with headache and visual field deficits [dosage, route, duration of treatment to reaction onset and outcome not stated]. [Extracted from the article]

A descriptive case study involving 23 patients, aged 6 weeks to 17 months, was conducted to investigate adverse reactions to various vaccines. The patients experienced a range of symptoms including fever, seizures, developmental delays, intellectual disabilities, and rash following immunization with different vaccines. The study provides a detailed account of the patients' reactions but does not specify the timing of the reactions or the outcomes. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 20-month-old girl developed reactivation of varicella zoster vaccine virus following vaccination with varicella zoster virus vaccine live and off-label treatment with dexamethasone for COVID-19 [routes not stated; not all dosages and times to reaction onset stated]. [Extracted from the article]

In a retrospective cohort study, a child with idiopathic nephrotic syndrome (INS) developed febrile neutropenia during treatment with rituximab as immunosuppressant therapy. The child received a single dose of rituximab 375 mg/m2, which led to depletions in B-cells and subsequent febrile neutropenia. The child also developed a varicella infection due to the depletions in B-cells and neutropenia. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 33-year-old man developed disseminated varicella zoster vaccine virus infection following contraindicated vaccination with varicella zoster virus vaccine for varicella immunisation and while receiving immunosuppressant drug therapy with mycophenolate, prednisone and tacrolimus [not all dosages stated; routes not stated]. [Extracted from the article]

An 18-month-old girl developed meningoencephalitis after receiving the MMR-varicella-zoster-virus vaccine. The girl had a primitive neuroectodermal tumor and was undergoing treatment, including chemotherapy and stem cell transplantations. After receiving the vaccine, she developed papulovesicular lesions on her hand, which were positive for varicella zoster virus (VZV). She was treated with aciclovir and foscarnet, and her neurological status improved within five days. She recovered from meningoencephalitis without any neurological complications. [Extracted from the article]

A case series published in Reactions Weekly describes two patients who developed Varicella zoster infection while receiving treatment for Graves' orbitopathy. One patient, a 76-year-old man, also experienced lack of efficacy during treatment for cognitive decline. The specific dosages and durations of the treatments were not provided in the report. It is worth noting that details of this case report have been previously published. [Extracted from the article]

A 45-year-old woman experienced a recurrent varicella zoster virus infection after receiving the SARS-COV-2-vaccine-inactivated-Sinovac-Biotech for COVID-19. She developed multiple pruritic vesicles and erythema on her head, neck, and trunk. The woman had a history of varicella in childhood and received the second dose of the vaccine three days before the appearance of symptoms. Reflectance confocal microscopy confirmed the diagnosis of recurrent varicella, and the infection was attributed to the vaccine. The woman was treated with famciclovir, and her lesions resolved after 10 days. [Extracted from the article]

This article reports on two cases of acute flaccid paralysis (AFP) following vaccination with either rabies vaccine or Varicella zoster virus vaccine live. In the first case, a 60-year-old woman developed lower limb weakness after receiving four doses of the rabies vaccine. The second case involved a 2-year-old boy who developed AFP of the lower limb 20 days after receiving the Varicella zoster virus vaccine live. The WHO-UMC causality scale indicated a probable relationship between the vaccines and AFP in both cases. [Extracted from the article]

A 22-year-old man developed disseminated varicella, a viral infection, while undergoing immunosuppressive therapy with tacrolimus, mycophenolate mofetil, and prednisone. He presented with pruritic skin lesions, epigastric pain, and other symptoms. The patient received treatment with aciclovir and eventually showed improvement, with his skin lesions healing and his overall condition improving. The case highlights the potential complications associated with immunosuppressive therapy. [Extracted from the article]

An 11-year-old boy experienced various complications during treatment for herpes zoster (HZ). He developed lymphopenia and lack of efficacy while taking aciclovir, and also experienced HZ ophthalmicus and HZ meningoencephalitis. Despite receiving the varicella zoster virus vaccine, he still developed these conditions, indicating vaccine failure. The boy's lymphocyte levels returned to normal six months later, and testing confirmed the presence of the vaccine strain in his cerebrospinal fluid. [Extracted from the article]

Healthcare professionals are reminded that live vaccines are contraindicated in people who are pregnant or significantly immunocompromised, says the Australian Therapeutic Goods Administration (TGA). There are two vaccines to prevent Japanese encephalitis in Australia: the live attenuated vaccine Imojev, and the non-live vaccine JEspect (also known as Ixiaro), notes the TGA. This particularly applies to the varicella (herpes) zoster vaccine [Zostavax] and the Japanese encephalitis vaccine [Imojev], as incorrect use of these live vaccines continues to be reported, says the TGA. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 14-month-old girl developed herpes zoster following immunization with varicella zoster virus vaccine live [ I dosage not stated i ]. At the 12 months of her age, she had received SC varicella zoster virus vaccine [Oka vaccine strain] on the right upper arm and measles and rubella virus vaccine on the left upper arm. [Extracted from the article]

She was administered varicella-zoster-virus-vaccine-live [live attenuated varicella vaccine; Oka vaccine strain]. Serology showed no past varicella infections along with varicella IgG antibody titer less than 50 mIU/mL was noted by ELISA. On the day of admission, based on the clinical presentation and history of varicella-zoster-virus-vaccine-live vaccination, she was diagnosed with vaccine-type strain varicella. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a review of 40 cases of herpesvirus activation, three patients [ I ages and sexes not stated i ] were described, who developed herpesvirus reactivation in (1 patient) and varicella-zoster-virus reactivation in (2 patients) during treatment with elasomeran and tozinameran [ I routes and dosages not stated i ]. Case 2:The patient after first dose of tozinameran [pfizer covid 19 vaccine] developed varicella-zoster-virus reactivation. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 42-year-old man developed disseminated primary varicella zoster infection during treatment with prednisolone and salmeterol/fluticasone-propionate for asthma [ I not all frequencies stated i ]. Based on these findings, he was diagnosed with disseminated primary varicella zoster infection, which was attributed to prednisolone and salmeterol/fluticasone-propionate. Chest radiograph showed diffuse nodular air space infiltrates in bilateral lungs consistent with varicella pneumonitis. [Extracted from the article]

Eventually, the development of his I Herpes zoster i infection was attributed was azathioprine. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 20-year-old man developed I Herpes zoster i infection during treatment with azathioprine for ileal Crohn's disease. Multi-dermatomal Herpes Zoster in a young patient with Crohn's disease on thiopurine therapy: Need for reconsidering vaccine recommendations. [Extracted from the article]